



Mycamine[®] (micafungin) – Expanded indication

- On December 20, 2019, the FDA approved Astellas's Mycamine (micafungin), for the treatment of candidemia, acute disseminated candidiasis, *Candida* peritonitis and abscesses without meningoen­cephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age.
 - The safety and effectiveness of Mycamine have not been established for the treatment of candidemia with meningoen­cephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age as a higher dose may be needed.
 - Mycamine has not been adequately studied in patients with endocarditis, osteomyelitis and meningoen­cephalitis due to *Candida*.
 - The efficacy of Mycamine against infections caused by fungi other than *Candida* has not been established.
- Mycamine is also approved in adult and pediatric patients 4 months of age and older for:
 - Treatment of candidemia, acute disseminated candidiasis, *Candida* peritonitis and abscesses
 - Treatment of esophageal candidiasis
 - Prophylaxis of *Candida* infections when undergoing hematopoietic stem cell transplantation.
- This use and dosage of Mycamine for the expanded indication are supported by evidence from adequate and well-controlled studies in adult and pediatric patients 4 months of age and older with additional pharmacokinetic and safety data in pediatric patients younger than 4 months of age.
- The most common adverse reactions (≥ 15%) with Mycamine use in pediatric patients younger than 4 months of age were sepsis, acidosis, anemia, oxygen saturation decreased and hypokalemia.
- The recommended dose of Mycamine for pediatric patients younger than 4 months of age for treatment of candidemia, acute disseminated candidiasis, *Candida* peritonitis and abscesses without meningoen­cephalitis and/or ocular dissemination is 4 mg/kg once daily via intravenous infusion.
- Refer to the Mycamine drug label for dosing for all its other indications.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.